Fresenius Kabi, a business segment of the health care group Fresenius, has signed definitive agreements to acquire APP Pharmaceuticals, Inc., a leading manufacturer of intravenously administered generic drugs (IV generics) in North America.
According to a Fresenius Kabi press release, APP shareholders will receive a cash purchase price of US$ 23.00 per share and a registered and tradeable Contingent Value Right (CVR) that could deliver up to US$ 6.00 per share, payable in 2011, if APP exceeds a cumulative adjusted EBITDA target for 2008 to 2010.
The whole story can be read here.
No comments:
Post a Comment